2 completed, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Oxi 4503: new trials by email Literature Review of Oxi 4503 trials Research Report on Oxi 4503
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS OXi4503 - Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes | Phase 1 | Terminated | University of Florida | 18 | 2011-02-01 | 2017-08-08 |
| Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden Combretastatin A1 Diphosphate (OXi4503) - Neoplasm Metastasis | Phase 1 | Completed | Mateon Therapeutics | 16 | 2009-07-01 | 2011-08-23 |
| Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors OXi4503 - Solid Tumors | Phase 1 | Completed | Mateon Therapeutics | 40 | 2005-07-01 | 2011-10-31 |
Carcinoma (1) · Carcinoma, Hepatocellular (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
Mateon Therapeutics (2) · University of Florida (1)
Australia (1) · United Kingdom (1) · United States (1)
Christopher R. Cogle, MD (1) · Jason Lickliter, MD (1) · Michael Brown, MD (1) · Michael Millward, MD (1) · Paul Mainwaring, MD (1)